They gave cancer patients 2000 IU vitamin D3 a day for 12 weeks to see if it lowers inflammation.

They gave cancer patients 2000 IU vitamin D3 a day for 12 weeks to see if it lowers inflammation.
the results?
Vitamin D3 lowered levels of Interleukin-6 (IL-6), a major inflammatory biomarker that forms a feedback cycle with estrogen and PTH.

The study in brief
Does vitamin D3 lower IL-6 in colorectal cancer patients?
In colorectal cancer patients with low vitamin D, 12 weeks of vitamin D3 lowered serum IL-6 by 39.3% compared with placebo (p = 0.001).
- Who was studied
- 126 colorectal cancer patients in Germany, operated on in the past year, with serum 25-hydroxyvitamin D below 60 nmol/L.
- What they did
- A randomized, double-blind trial gave a personalized loading dose of vitamin D3, then 2000 IU a day (61 patients), or placebo (65 patients) for 12 weeks.
- What they found
- The 95% confidence interval for the IL-6 reduction was -54.9% to -18.2%. IFN-gamma (-6.7%, p = 0.69) and MMP-1 (-5.4%, p = 0.23) did not change significantly.
- What it does not show
- The study measured three blood markers over 12 weeks, not tumor growth, recurrence or survival. The trial is still ongoing.
- Note on the post above
- The abstract does not mention estrogen or PTH, and patients got a personalized loading dose before the 2000 IU a day.
Summary written from the PubMed abstract, not from the full paper.
The study
- Effects of personalized vitamin D(3) on inflammation in colorectal cancer patients: a randomized trialBr J Cancer · 2026 · PMID 41507560